Donor T cells against cytomegalovirus infection after a stem cell transplant
Tests donor T cells aimed at cytomegalovirus in people after stem cell transplant.
Key facts
- Who runs it
- Mari Dallas
- Where
- Cleveland, United StatesSee the site
- Trial code
- Registry title
- T Cell Therapy of Opportunistic Cytomegalovirus Infection
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 20 people, planned
- Started
- 27 May 2020
- Expected to end
- Aug 2028
- Type of study
- Interventional
- Treatments tested
- CMV specific adoptive t-cells
- Record updated
- 22 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who had a stem cell transplant from a donor and now have a CMV (cytomegalovirus) infection. The infection must not respond to, or not be treatable with, usual antiviral drugs, or must have come back a second time.
- Age
- 3 months and older. T-cell donors must be 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- More than 30 days after an allogeneic (donor) hematopoietic stem cell transplant. CMV infection or reactivation, with virus in the blood (>1000 copies/ml) or CMV symptoms. ECOG performance status ≤ 3 (people can still at least partly care for themselves).
- Earlier treatment
- One of these is needed: viral load did not fall by at least 1 log (10-fold) after ≥ 14 days of ganciclovir, valganciclovir or foscarnet; CMV symptoms are new, lasting or worse during these drugs; these drugs cannot be used or caused side effects; or this is a second return of CMV. No antithymocyte globulin within 28 days and no virus-specific T cells within 6 weeks (42 days) before the infusion.
- Biomarker or test result
- CMV in the blood above 1000 copies/ml, unless there are CMV symptoms. The related donor must share at least 3/6 HLA tissue-type markers and have a positive CMV blood test.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Opportunistic viral infections other than CMV
- Active grade 2-4 acute graft vs. host disease (GVHD) or chronic GVHD
- Any condition needing high-dose steroids (>0.5 mg/kg/day prednisone or equivalent)
- Antithymocyte globulin within 28 days or virus-specific T cells within 6 weeks (42 days) before the infusion
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration
- Patients must have documented opportunistic CMV infection, or reactivation; the criteria include (both of the following criteria must be met); Patients may have asymptomatic viremia (>1000 copies/ml) OR presence of symptoms secondary to CMV infection, AND; Patients must have ONE OF THE NEXT FOUR CRITERIA:; Absence of an improvement of viral load after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log, i.e. 10-fold) or; New, persistent and/or worsening CMV-related symptoms, signs and/or markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet, or; Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir or foscarnet; Second recurrence of CMV viremia, CMV-related symptoms, signs and/or markers of end organ compromise
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3
- Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment
- Subjects must have the ability to understand and the willingness to sign a written informed consent document, or assent document
Who cannot take part
- Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells
- Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion; Donor eligibility
- Patients with opportunistic viral infections other than CMV
- Patients with active, grade 2-4, acute graft vs. host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (>0.5 mg/kg/day prednisone or its equivalent) as treatment
- Must meet the criteria for donor selection defined in the Standard Operating Procedures of University Hospitals Seidman Cancer Center Stem Cell Transplant Program
- Age ≥ 18 years
- Pregnant or breastfeeding women are excluded from this study
- Related donor of T cells must be at least partially HLA compatible, matching with recipient in at least 3/6 HLA loci (HLA-A, HLA-B, and HLA-DRB1 loci will be considered for this)
- Must have evidence of a serologic response (i.e. be seropositive) against CMV
- Must be capable of undergoing a single standard 2 blood volume leukapheresis or donation of one unit of whole blood
Where in United States
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer CenterCleveland, United StatesContact: Mari H Dallas, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV.
Read full original descriptionShow less
Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).
The group in the trial
- CMV specific adoptive t-cellsTreatment being tested
This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant
- Plain-language title
- Donor T cells against cytomegalovirus infection after a stem cell transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 22 October 2025